Publications by authors named "L Stranix-Chibanda"
Article Synopsis
- Managing HIV during pregnancy involves addressing both medical needs and the psychological aspects of the mother's health.
- Effective care plans aim to maintain low HIV levels and enhance the mother's overall health before conception.
- The article discusses the use of antiretroviral drugs, pregnancy outcomes for mothers with HIV, and the importance of a comprehensive approach to care.
Changes in peripheral quantitative computed tomography measured bone density, size, and strength in Zimbabwean children with and without HIV over one year: a cohort study.
J Bone Miner Res
November 2024
Article Synopsis
- Understanding bone growth in adolescents with HIV could help improve their skeletal health and decrease fracture risk later in life.
- The study compared bone mineral density and strength between children with HIV on antiretroviral therapy and those without HIV, revealing that children with HIV generally had lower bone measurements but similar increases over time.
- Notably, height-for-age scores were found to influence how HIV affected bone growth, impacting females more significantly in terms of bone density and strength changes.
Background: Safety data from randomized trials of antiretrovirals in pregnancy are scarce. We evaluated maternal bone and renal data from the International Maternal Pediatric Adolescent AIDS Clinical Trials Network 2010 trial, which compared the safety and efficacy of 3 antiretroviral therapy regimens started in pregnancy: dolutegravir + emtricitabine/tenofovir alafenamide (DTG + FTC/TAF), dolutegravir + emtricitabine/tenofovir disoproxil fumarate (DTG + FTC/TDF), and efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF).
Methods: A subset of participants underwent dual-energy X-ray absorptiometry scans at postpartum week 50 only.
Objective: Tenofovir alafenamide (TAF)-based antiretroviral therapy (ART) regimens have been associated with adverse changes in lipid and glucose profiles compared with tenofovir disoproxil fumarate (TDF)-based ART, but data in pregnancy is limited. We evaluated metabolic markers in pregnant women with HIV after starting TAF- vs TDF-based ART.
Methods: We analyzed data within the IMPAACT 2010/VESTED trial, which demonstrated better pregnancy outcomes in pregnant women randomized to initiate TAF/Emtricitabine/Dolutegravir (TAF/FTC+DTG; n=217) or TDF/FTC+DTG (n=215).
Background: SARS-CoV-2 seropositivity data in women living with HIV (WLHIV), their infants and associated factors in this subpopulation remain limited. We retrospectively measured SARS-CoV-2 seropositivity from 07/2020-11/2021 among WLHIV and their children in the PROMOTE observational cohort in Uganda, Malawi, and Zimbabwe prior to widespread SARS-CoV-2 vaccination in those countries.
Methods: Plasma stored during 3 waves of the COVID-19 pandemic in East/Southern Africa were tested for SARS-CoV-2 specific IgG antibodies (Ab) using serological assays that detect adaptive immune responses to SARS-CoV-2 spike protein.